US FDA pauses Gilead trials testing experimental HIV pill combination
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
FDA clinical hold a 'blow to Gilead Sciences (GILD) HIV pipeline - Oppenheimer
June 10, 2025 11:14 AM EDTOppenheimer analyst Hartaj Singh reiterated an Outperform rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD) but said the clinical hold is a 'blow' to the company's HIV pipeline.
The analyst commented, "This morning, Gilead announced that the FDA had put ongoing GS-4182+GS-1720... More
